NCT05074121

NAC for Attenuation of COVID-19 Symptomatology

N-acetylcysteine for Attenuation of COVID Symptomatology

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Cambridge Health Alliance · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The objective of this study is to determine whether oral NAC is effective at attenuating COVID-19 disease symptom severity and duration of symptoms.

Detailed description

STUDY DESIGN: Randomized double-blinded placebo-controlled trial ELIGIBILITY Inclusion criteria: * age 18 years and older * participants will need daily access to use of a smartphone for at least six weeks from time of enrollment * Positive COVID-19 test within 10 days of date of enrollment * not already hospitalized for treatment of COVID Exclusion criteria: * pregnant * already hospitalized for treatment of COVID PROTOCOL * 50:50 randomization: half of participants will take NAC, half will take placebo * Participants will take NAC/placebo following this outpatient protocol: * 2400 mg x 1 PO then * 1200 mg PO BID x 14 days * Participants will complete an online symptom-tracker for six weeks (daily for three weeks, weekly for three weeks)

Conditions

• Covid19
• COVID-19 Pneumonia
• COVID-19 Respiratory Infection
• COVID-19 Lower Respiratory Infection
• SARS-CoV2 Infection
• SARS-CoV-2 Acute Respiratory Disease
• SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
• Oxidative Stress

Interventions

Type	Name	Description
DRUG	N-acetylcysteine	N-acetylcysteine
OTHER	Placebo	Placebo

Timeline

• Start date: 2024-03-31
• Primary completion: 2024-12-31
• Completion: 2025-02-01
• First posted: 2021-10-12
• Last updated: 2023-08-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study